Few drugs have moved from the medical literature to everyday conversation as fast as tirzepatide. It is sold as Mounjaro and Zepbound, it keeps producing headline-sized trial results, and it has also become a magnet for grey-market sales. This guide separates what the published research actually shows from the hype around it, using primary sources wherever we could. It is information for readers, not medical advice.
Editorial note: tirzepatide is an FDA-approved prescription medicine. This site is a directory of research-peptide suppliers, and nothing here is dosing, sourcing or treatment guidance. Where we cite figures, the source is linked at the end. We have not tested any product.
What tirzepatide is
Tirzepatide is a 39-amino-acid synthetic peptide built on the sequence of GIP, the glucose-dependent insulinotropic polypeptide, and modified so that it activates two receptors at once: the GIP receptor and the GLP-1 receptor. That dual action is the central idea. Semaglutide, the other household name in this class, activates only the GLP-1 receptor. Tirzepatide is also attached to a fatty-acid side chain that lets it bind albumin in the blood, which is what allows a once-weekly injection.
It is approved in the United States under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management, and Zepbound also carries an approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Those are pharmaceutical products, made under regulatory controls, prescribed by clinicians, and supported by large randomized trials. That regulatory status matters for everything that follows.
The headline result: tirzepatide versus semaglutide
The comparison that drove most of the attention is SURMOUNT-5, a head-to-head, open-label trial in about 750 adults with obesity or overweight plus at least one weight-related condition. Published in the New England Journal of Medicine, it reported average weight loss of 20.2% with tirzepatide against 13.7% with semaglutide at 72 weeks, a difference of 6.5 percentage points. In kilograms that was roughly 22.8 versus 15.0. Waist circumference fell by about 18 cm on tirzepatide and 13 cm on semaglutide. Side effects were mainly gastrointestinal, consistent with earlier trials.
Two cautions are worth holding onto. First, those are average results at the highest tolerated doses, not a prediction for any individual. Second, the design was open-label, meaning participants and investigators knew which drug was being used, which is normal for a trial comparing two injectables but is a limitation. The result is genuinely strong evidence that tirzepatide produces larger average weight loss than semaglutide in this setting. It does not tell you what any one person will experience.
The newest big study: keeping weight off
The most recent major trial result is SURMOUNT-MAINTAIN, published in The Lancet in May 2026, and it asks a question people care about: what happens when treatment is reduced or stopped? The trial enrolled 441 US adults with obesity in a 60-week open-label weight-loss phase. Of those, 378 who had lost at least 5% of their body weight and tolerated at least 10 mg were then randomized into a 52-week double-blind maintenance phase: continue at their maximum tolerated dose, drop to a 5 mg dose, or switch to placebo.
At 112 weeks, average weight change from the start of the trial was minus 21.9% for those who continued the maximum tolerated dose, minus 16.6% for the 5 mg group and minus 9.9% for placebo. Only 8% of the maximum-dose group and 25% of the 5 mg group regained at least half of their lost weight, compared with 67% of the placebo group. Participants who regained more than half of their loss could receive rescue tirzepatide, so the placebo figure understates how much weight might be regained with no further treatment. The takeaway reported by the investigators and an accompanying editorial is that continued therapy matters for long-term management, and that a reduced dose retained a good share of the benefit. Adverse events were more common with tirzepatide than placebo, mostly mild-to-moderate gastrointestinal effects.
Beyond weight: the heart
Weight is only part of the story, and cardiovascular outcomes are where the most consequential data sit. SURPASS-CVOT compared tirzepatide with dulaglutide, an older GLP-1 drug with proven cardiovascular benefit, in people with type 2 diabetes and established cardiovascular disease. Published in the New England Journal of Medicine in 2025, it met its prespecified goal of non-inferiority for major adverse cardiovascular events, with a hazard ratio of about 0.92 and a confidence interval (0.83 to 1.01) that just crossed 1.0. In plain terms, tirzepatide was shown to be at least as protective as dulaglutide, with a numerical edge that was not statistically conclusive. A lower rate of death from any cause was reported, but that was an exploratory finding and should not be over-read.
It is also important to know what this is not. It is not a trial against placebo, so it does not directly measure how much cardiovascular risk tirzepatide removes compared with no treatment. Analyses that try to estimate that by indirect comparison exist, but they are exactly that: estimates.
Early-stage science: brown fat in mice
Some of the newest headlines are about mechanism. In September 2026, researchers at the University of Barcelona reported in the journal Biomedicine and Pharmacotherapy that tirzepatide activated brown adipose tissue, the calorie-burning type of fat, in obese mice. Crucially, they compared the treated animals with untreated mice given the same amount of food, which let them separate effects of the drug from effects of eating less. The finding suggests tirzepatide may influence energy expenditure in addition to suppressing appetite.
The authors themselves are careful: this is a mouse study, and mouse and human metabolism, and fat distribution, differ substantially. Brown fat is also less abundant in adult humans. It is a hypothesis-generating result, a reason for further human research, and not evidence that the drug does the same thing in people. Treat articles that present it as established fact with suspicion.
Where the hype outruns the evidence
Three patterns recur whenever a drug becomes this famous.
Dose and speed folklore. Online communities trade ideas about higher doses, faster escalation, and unusual regimens. The evidence base is the approved regimens used in the trials. The FDA has said it received reports of adverse events that may relate to patients using compounded semaglutide or tirzepatide products at doses beyond those in the approved label, including more product per dose, more frequent doses, or faster escalation. Some of the events were serious.
Surrogate-endpoint enthusiasm. Every new mechanistic paper, in mice or in a post-hoc analysis, is quickly framed as a new benefit. Post-hoc subgroup analyses and observational cohort studies are useful for generating questions, but they are weaker than randomized trials, and they are frequently reported without those caveats.
Equating every product with the approved drug. This is the most consequential one, and it brings us to the market around the drug.
The grey market: what the FDA says
Because demand has outstripped supply for long stretches, a large market has grown up in compounded versions and in products labeled for laboratory use. The FDA maintains a page on unapproved GLP-1 drugs, last updated October 1, 2026, and it is unusually direct. It says compounded drugs are not FDA-approved and the agency does not review them for safety, effectiveness or quality before they are marketed, and that compounded drugs should only be used in patients whose medical needs cannot be met by an approved drug.
It also describes problems it has seen: fraudulent products whose labels name pharmacies that do not exist, dosing errors resulting from patients measuring doses themselves, injectable products that arrived warm without enough ice packs, and concerns about multi-dose vials used beyond 28 days. As of May 31, 2026, the agency had received more than 730 adverse-event reports associated with compounded tirzepatide, with the caveat that it is not always possible to tell whether a drug caused an event, and that underreporting is likely because many compounders are not required to report.
Most relevant to a site like this one, the FDA states that it has warned companies selling unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled "for research purposes" or "not for human consumption," when those products are being sold directly to consumers for human use with dosing instructions. It urges consumers not to purchase them, describing them as of unknown quality and potentially harmful. The agency also states that retatrutide and cagrilintide cannot be used in compounding under federal law.
Our position, stated plainly
PeptideSuppliers.org lists suppliers of research peptides and reviews their public documentation. We do not endorse any product for human use, we do not give dosing guidance, and we do not treat a certificate of analysis as a substitute for regulatory oversight. A COA is a lab report about one sample from one batch. It cannot establish sterility, safety, or suitability for injection, and for a drug as widely used as tirzepatide, an approved product dispensed through a licensed pharmacy is a different thing altogether from a vial sold as a research chemical.
Some suppliers in our database list tirzepatide or related compounds in their catalogs. Where we mention them, we are reporting what they sell, not recommending it. If you are considering any GLP-1 or GIP medication for a health reason, the right conversation is with a licensed clinician, and the right source is a state-licensed pharmacy, as the FDA advises. If you are a researcher working with these compounds in vitro or in animals, the documentation checks we describe elsewhere on the site apply, along with your institution's rules and the law where you are.
What to watch next
The research pipeline is moving quickly, and several things are worth following: further analyses from SURMOUNT-MAINTAIN on lower-dose strategies; long-term outcome trials in heart failure, kidney disease and liver disease; human studies on whether the brown-fat finding translates; and the growing list of competing and next-generation agents, from triple agonists to oral drugs. The honest summary today is that tirzepatide has some of the strongest randomized evidence of any weight-management drug, that it is a prescription medicine with real side effects, and that much of what circulates online about it, especially around unapproved versions, goes well beyond what the evidence supports.
Sources
- FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026)
- American College of Cardiology, SURMOUNT-MAINTAIN: Continuing Tirzepatide Maintains Weight Loss (May 18, 2026), summarizing Horn et al., The Lancet, 2026
- ScienceDaily / University of Barcelona, Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat (September 26, 2026)
- Aronne et al., SURMOUNT-5, New England Journal of Medicine, 2025 (doi 10.1056/NEJMoa2416394)
- Nicholls et al., SURPASS-CVOT, New England Journal of Medicine, 2025;393:2409-2420
For informational purposes only. Not medical advice. See our medical disclaimer.